

Accelerate Diagnostics, Inc  
Form 8-K  
September 27, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported) **September 25, 2018**

**Accelerate Diagnostics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-31822**

(Commission File Number)

**84-1072256**

(IRS Employer Identification No.)

**3950 South Country Club Road, Suite 470, Tucson, Arizona**

(Address of principal executive offices)

**85714**

(Zip Code)

**(520) 365-3100**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 25, 2018, Joan Martin resigned from his position as Executive Vice President and Head of Europe, Middle East, and Africa of Accelerate Diagnostics, Inc. (the “Company”), effective immediately. Lawrence Mehren, President and Chief Executive Officer of the Company, will oversee operations of the region on an interim basis until the vacancy is filled.

On September 27, 2018, the Company issued a press release regarding Mr. Martin’s resignation. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits. The following materials are filed as exhibits to this Current Report on Form 8-K:

**Exhibit**

**Number Description**

---

99.1      Press Release, dated September 27, 2018

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCELERATE DIAGNOSTICS, INC.

(Registrant)

/s/ Steve Reichling \_\_\_\_\_

Date: September 27, 2018

Steve Reichling

Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit**  
**Number Description** \_\_\_\_\_

99.1      Press Release, dated September 27, 2018